Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

Abstract Background The Dominantly Inherited Alzheimer Network Trials Unit (DIAN‐TU) adaptive platform trial has launched the first of three tau drugs in the tau Next Generation Prevention Trial (tau NexGen), starting with the combination of anti‐tau monoclonal antibody etalanetug (E2814) and anti‐amyloid‐beta antibody lecanemab. Herein, we provide the first results of lecanemab (open‐label) on amyloid PET in a symptomatic DIAD population (the asymptomatic cohort will be evaluated later). Methods The DIAN‐TU‐001 Tau NexGen Trial (NCT05269394) is a phase II/III randomized, double blinded, placebo‐controlled trial in participants with DIAD. Eligible mutation‐positive participants were enrolled in 2 cohorts (Cohort 1: Symptomatic Population (CDR=0.5‐1), n=97; Cohort 2: Asymptomatic Population (CDR=0), n=100). The symptomatic Cohort 1 received open‐label lecanemab at Week 0 for 6 months and were then randomized to receive concurrent E2814 or placebo; meanwhile, asymptomatic Cohort 2 was randomized to E2814 or placebo at Week 0 and then received open‐label lecanemab at Week 52. For Cohort 1, amyloid PET ([ 11 C]PiB‐PET) was performed at baseline (Week 0) and Week 24, and then at the weeks 52, 104, and 208 visits. Change on amyloid PET from Week 0 to Week 24 is a secondary endpoint for Cohort 1. Results Preliminary Week 24 amyloid PET data was available from 62 symptomatic participants receiving lecanemab (avg EYO=1.51 and avg age= 47.4). Baseline mean amyloid PET SUVr was 2.06 (SD=0.38) (equivalent to 99.9 (SD=39.5) Centiloids (CL)) and SUVr=3.63 (SD=0.99) with partial volume correction (PVC). The change from baseline in amyloid PET SUVr at 24 weeks was ‐0.18 (SD=0.17) (equivalent to ‐18.6 CL (SD=17.3)) and SUVR=‐0.43 (SD=0.49) with PVC. The six‐month amyloid clearance results in participants with DIAD are consistent with pharmacokinetic (PK)/pharmacodynamic (PD) modeling in sporadic Alzheimer’s disease, with faster rate of amyloid clearance in older patients and those with lower baseline amyloid. Conclusions Lecanemab reduced amyloid PET in symptomatic participants with DIAD at Week 24. The reduction in amyloid PET was in line with predictions based on PK/PD modeling developed from sporadic AD.

What this study adds

Evidence grade: High

The record lists 97 participants. In this early report, six months of open-label lecanemab cleared amyloid in the brains of 62 people with dominantly inherited Alzheimer's disease, matching what is seen in sporadic Alzheimer's disease. These are preliminary results from only the symptomatic group; the asymptomatic group has not yet been evaluated, so no conclusions about preventing or slowing disease can be drawn.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Wildsmith, K. R., Charil, A., Benzinger, T. L., Gordon, B. A., Bhagunde, P. R., Li, D., et al. (2025). Lecanemab in DIAD: 6‐Month Amyloid PET Results from the DIAN‐TU‐001 Trial. Alzheimer s & Dementia. https://doi.org/10.1002/alz70859_105303

Vancouver

Wildsmith KR, Charil A, Benzinger TL, Gordon BA, Bhagunde PR, Li D, et al. Lecanemab in DIAD: 6‐Month Amyloid PET Results from the DIAN‐TU‐001 Trial. Alzheimer s & Dementia. 2025. doi:10.1002/alz70859_105303. PMID: 41447716.

BibTeX

@article{wildsmith2025-41447716,
  author  = {Wildsmith, Kristin R. and Charil, Arnaud and Benzinger, Tammie L.S. and Gordon, Brian Andrew and Bhagunde, Pratik R. and Li, David and Wang, Guoqiao and Reyderman, Larisa and others},
  title   = {{Lecanemab in DIAD: 6‐Month Amyloid PET Results from the DIAN‐TU‐001 Trial}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70859_105303},
  pmid    = {41447716},
  url     = {https://doi.org/10.1002/alz70859_105303}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this early report, six months of open-label lecanemab cleared amyloid in the brains of 62 people with dominantly inherited Alzheimer's disease, matching what is seen in sporadic Alzheimer's disease. These are preliminary results from only the symptomatic group; the asymptomatic group has not yet been evaluated, so no conclusions about preventing or slowing disease can be drawn.

Study details

How this study scored 48/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 0 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 48 of 100.48 of 100 points earned52 not earned

Published in a peer-reviewed journal. Scored zero for study design and effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 97 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.7 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 1.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Randall John Bateman: h-index 101 (OpenAlex, whole career)
Institution's track record 2 / 3 Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41447716)
Free to read 2 / 2 Free to read
Total 48 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Biomarkers from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →